researching K-RAS

For those interested in Phoremost's lead oncology program which has already identified lead drug candidates to a novel target of mutant K-RAS cancers, I've found an interesting nature.com article titled
'Cancer: The RAS Renaissance' published 15 April 2015.

http://www.nature.com/news/cancer-the-ras-renaissance-1.17326

The article gives a history of research into the RAS family and the three different forms: K-RAS, N-RAS and H-RAS.
It mentions some current research and though Phoremost & Cambridge Uni are not mentioned the article gives a very good insight into the area Phoremost is working in.
Here's a couple of quotes:
"Fesik says that the solutions to Ras's puzzles, whatever they are, will probably emerge from academic institutions. He left pharma in part because he loved the pursuit of important targets, regardless of how easy or hard they are to hit. Chasing an undruggable protein can be difficult to justify in industry, where scientific interest must often take a backseat to the near-term potential for profit. “Most pharma companies don't want to take the risk to go after these undruggable targets, and if they do, it's temporary,” he says............."
"Stockwell says he hopes that the recent revival of research on Ras proteins could inspire scientists studying other intractable targets. “If there is some success there, maybe that excitement will extend to other targets,” he says. “If we really want to impact disease, there's this vast space of additional targets that have never been mined........."
......................
SoT